The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Skeletal Benefits of Alendronate: 7-Year Treatment of Postmenopausal Osteoporotic Women1
Abstract
We report here the second 2-yr extension of a clinical trial among postmenopausal women; 235 women continued blinded treatment with 5 or 10 mg alendronate daily, and 115 women who had been treated with alendronate for 5 yr were switched to blinded placebo. Continuous treatment with alendronate (10 mg daily) for 7 yr increased lumbar spine bone mineral density (BMD) by 11.4% compared to baseline. After the initial 18 months, each additional year of treatment through yr 7 increased spine BMD by 0.8% for the 10-mg dose and 0.6% for the 5-mg dose, with significant increases during yr 6-7. Previously reported increases in BMD at other skeletal sites and decreases in biochemical markers of bone turnover remained stable during yr 6-7. Among women previously taking alendronate for 5 yr who were switched to placebo, there was no significant decline in BMD at the spine or hip, whereas small, but significant, decreases in BMD at the forearm and total body and small increases in biochemical markers were observed. The safety and tolerability profiles were similar to those of placebo. This is the largest published long-term study of antiresorptive therapy. Our findings indicate that long-term alendronate treatment is well tolerated and effective for 7 yr. Increases in spinal BMD continue for at least 7 yr, and other skeletal benefits are maintained. Discontinuation does not lead to accelerated bone loss, but continuous treatment yields better skeletal benefits than shorter treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis
Dr. Garnero, P., Sornay-Rendu, E., Chapuy, M.-C., & Delmas, P. D. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110307 · Cited by 1,001
Guidelines for diagnosis and management of osteoporosis
Kanis, J. A., Delmas, P., Burckhardt, P., Cooper, C., & Torgerson, D. (1997) · Osteoporosis International · doi:10.1007/bf01623782 · Cited by 790
Prevention of spinal osteoporosis in oophorectomised women
Lindsay, R., Hart, D. M., Forrest, C., & Baird, C. (1980) · The Lancet · doi:10.1016/s0140-6736(80)92592-1 · Cited by 706
Mashiba, T., Hirano, T., Turner, C. H., Forwood, M. R., Johnston, C. C., & Burr, D. B. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.4.613 · Cited by 688
Pols, H. A. P., Felsenberg, D., Hanley, D. A., Štepán, J., Muñoz-Torres, M., Wilkin, T. J., Qin-sheng, G., Galich, A. M., Vandormael, K., Yates, A. J., et al. (1999) · Osteoporosis International · doi:10.1007/pl00004171 · Cited by 593
The socioeconomic burden of fractures: Today and in the 21st century
Johnell, O. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)90023-1 · Cited by 495
Antifracture Efficacy of Antiresorptive Agents Are Related to Changes in Bone Density
Wasnich, R. D. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.1.231 · Cited by 417
Self-citationBalena, R., Toolan, B. C., Shea, M., Markatos, A., Myers, E. R., Lee, S. C., Opas, E. E., Seedor, J. G., Klein, H., & Frankenfield, D. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116872 · Cited by 396
Cited by
Severely Suppressed Bone Turnover: A Potential Complication of Alendronate Therapy
Odvina, C. V., Zerwekh, J. E., Rao, D. S., Maalouf, N., Gottschalk, F. A., & Pak, C. Y. C. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0952 · Cited by 1,432
Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women
Bone, H. G., Hosking, D., Devogelaer, J.-P., Tucci, J. R., Emkey, R. D., Tonino, R. P., Rodriguez-Portales, J. A., Downs, R. W., Gupta, J., Santora, A. C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030897 · Cited by 1,347
Self-citationNancollas, G. H., Tang, R., Phipps, R. J., Henneman, Z., Gulde, S., Wu, W., Mangood, A., Russell, R. G. G., & Ebetino, F. H. (2006) · Bone · doi:10.1016/j.bone.2005.05.003 · Cited by 862
Bekker, P. J., Holloway, D. L., Rasmussen, A. S., Murphy, R., Martin, S. W., Leese, P. T., Holmes, G. B., Dunstan, C. R., & DePaoli, A. M. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040305 · Cited by 771
Denosumab and bisphosphonates: Different mechanisms of action and effects
Baron, R., Ferrari, S., & Russell, R. G. G. (2011) · Bone · doi:10.1016/j.bone.2010.11.020 · Cited by 715
Metadata
- Authors
- Tonino, R. P., Meunier, P. J., Emkey, R., Rodriguez-Portales, J. A., Menkes, C.-J., Wasnich, R. D., Bone, H. G., Santora, A. C., Wu, M., Desai, R., & Ross, P. D.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2000-09
- Volume
- 85
- Issue
- 9
- Pages
- 3109-3115
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2172119280
- Cited by
- 335
- References
- 31
- FWCI
- 25.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Skeletal Benefits of Alendronate: 7-Year Treatment of Postmenopausal Osteoporotic Women1. https://app.cochat.ai/papers/10.1210/jcem.85.9.6777
- The paper
- Tonino, R. P., Meunier, P. J., Emkey, R., Rodriguez-Portales, J. A., Menkes, C.-J., Wasnich, R. D., Bone, H. G., Santora, A. C., Wu, M., Desai, R., & Ross, P. D. (2000). Skeletal Benefits of Alendronate: 7-Year Treatment of Postmenopausal Osteoporotic Women1. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jcem.85.9.6777
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.